-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $165

Benzinga·07/30/2026 18:14:29
Listen to the news
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $88 to $165.